title: Development of a highly productive and scalable plasmid DNA production platform.
abstract: With the applications of DNA vaccines extending from infectious diseases to cancer, achieving the most efficient, reproducible, robust, scalable, and economical production of clinical grade plasmid DNA is paramount to the medical and commercial success of this novel vaccination paradigm. A first generation production process based on the cultivation of Escherichia coli in a chemically defined medium, employing a fed-batch strategy, delivered reasonable volumetric productivities (500-750 mg/L) and proved to perform very well across a wide range of E. coli constructs upon scale-up at industrial scale. However, the presence of monosodium glutamate (MSG) in the formulation of the cultivation and feed solution was found to be a potential cause of process variability. The development of a second generation process, based on a defined cultivation medium and feed solution excluding MSG, was undertaken. Optimization studies, employing a plasmid coding for the HIV gag protein, resulted in cultivation conditions that supported volumetric plasmid titers in excess of 1.2 g/L, while achieving specific yields ranging from 25 to 32 microg plasmid DNA/mg of dry cell weight. When used for the production of clinical supplies, this novel process demonstrated applicability to two other constructs upon scale-up in 2,000-L bioreactors. This second generation process proved to be scalable, robust, and highly productive.
authors.affiliation: Bioprocess R&D, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
authors.forename: K
authors.initials: K
authors.lastname: Listner
authors.forename: L
authors.initials: L
authors.lastname: Bentley
authors.forename: J
authors.initials: J
authors.lastname: Okonkowski
authors.forename: C
authors.initials: C
authors.lastname: Kistler
authors.forename: R
authors.initials: R
authors.lastname: Wnek
authors.forename: A
authors.initials: A
authors.lastname: Caparoni
authors.forename: B
authors.initials: B
authors.lastname: Junker
authors.forename: D
authors.initials: D
authors.lastname: Robinson
authors.forename: P
authors.initials: P
authors.lastname: Salmon
authors.forename: M
authors.initials: M
authors.lastname: Chartrain
mesh_terms: D019149:Bioreactors; D001709:Biotechnology / Q000379:methods*; D002469:Cell Separation; D002851:Chromatography, High Pressure Liquid; D003470:Culture Media / Q000378:metabolism; D004247:DNA / Q000737:chemistry*; D004926:Escherichia coli / Q000378:metabolism; D005434:Flow Cytometry; D005990:Glycerol / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D010957:Plasmids / Q000378:metabolism*; D013050:Spectrometry, Fluorescence; D013997:Time Factors; D019444:Vaccines, DNA / Q000737:chemistry
chemical_list: D003470:Culture Media; D019444:Vaccines, DNA; D004247:DNA; D005990:Glycerol